Most Viewed Abstracts
1. Report Shows Shift in Starting Salaries for Physicians 2. Recommendations on the use of 18F-FDG PET in oncology 3. Taxane-based combinations as adjuvant chemotherapy of early breast cancer: a meta-analysis of randomized trials 4. Gene expression signatures, clinicopathological features, and individualized therapy in breast cancer 5. Sentinel node biopsy is important in mastectomy for ductal carcinoma in situ
Top Ten Searches
brca1 prostate-specific antigen sclc fobt egd bmi dysplasia hematologic ovarian hccYour Article Summary
Cancer mortality in patients with schizophrenia
Cancer, 06/30/09
Tran E et al. - In a study to explore the relationship between cancer mortality and schizophrenia, the results of the current study demonstrated an increased risk of mortality by cancer in pts with schizophrenia, especially for women from breast cancer and for men from lung cancer.
Methods- In 1993, a large prospective study was initiated in a cohort of 3470 pts with schizophrenia to examine cancer-related mortality and predictors.
- Standardized mortality ratios (SMRs) were calculated, adjusting for age and sex relative to a representative sample of the French general population.
- During the 11-yr follow-up, 476 (14%) pts died; the mortality rate was nearly 4-fold higher than in the general population.
- Cancer was the second most frequent cause of mortality (n=74), with a global SMR of 1.5.
- For all cancers, the SMRs were 1.4 (not significant) for men and 1.9 for women.
- For men, lung cancer was the most frequent localization (n=23; 50%), with an SMR of 2.2.
- For women, breast cancer was the most frequent localization (n=11; 39%), with an SMR of 2.8.
- In comparison with pts who did not die of cancer, there were 2 significant baseline predictors of death by lung cancer in the final logistic regression model: duration of smoking and age >38 yrs.
Today in Breast...keeping you current
Receive free subspecialty "5-minute updates" via email
Local excision alone without irradiation for ductal carcinoma in situ of the breast: A trial of the Eastern Cooperative Oncology Group
Journal of Clinical Oncology, 10/19/09
Docetaxel versus docetaxel alternating with gemcitabine as treatments of advanced breast cancer: final analysis of a randomised trial
Annals of Oncology, 10/13/09
Pomegranate fruit extract impairs invasion and motility in human breast cancer
Integrative Cancer Therapies , 10/12/09
Today in Lung/Thoracic Oncology...keeping you current
Receive free subspecialty "5-minute updates" via email
Oestrogen plus progestin and lung cancer in postmenopausal women (Womens Health Initiative trial): a post-hoc analysis of a randomised controlled trial
The Lancet, 10/12/09
Prognostic and predictive factors in a randomized phase III trial comparing cisplatin-pemetrexed versus cisplatin-gemcitabine in advanced non-small-cell lung cancer
Annals of Oncology, 10/19/09
Maintenance pemetrexed plus best supportive care versus placebo plus best supportive care for non-small-cell lung cancer: A randomised, double-blind, phase III study
The Lancet, 10/26/09
Sponsor
Article Search
Sponsor
Sponsor


See Latest Articles


